Constitutively Active Akt Contributes to Vincristine Resistance in Human Retinoblastoma Cells

被引:12
作者
Zhang, Hao [1 ]
Li, Bin [1 ]
Bai, Shu-wei [1 ]
Wang, Hui-juan [1 ]
机构
[1] Capital Med Univ, Beijing Tong Ren Hosp, Beijing Tong Ren Eye Ctr, Beijing Inst Ophthalmol, Beijing 100005, Peoples R China
基金
中国国家自然科学基金;
关键词
Drug resistance; Akt; Vincristine; P-glycoprotein; Retinoblastoma; P-GLYCOPROTEIN EXPRESSION; OVARIAN-CANCER CELLS; MULTIDRUG-RESISTANCE; PI3K/AKT PATHWAY; CHEMOTHERAPY; APOPTOSIS; CHEMORESISTANCE; ACTIVATION; MECHANISMS; INHIBITOR;
D O I
10.3109/07357900903179641
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Akt mediates survival signals which preserve various cancer cells from apoptosis. Its correlation with chemoresistance of cancer cells has attracted much attention. But how Akt affects vincristine-induced cell death in retinoblastoma is unknown. Here we show that Akt activity is involved in vincristine-induced cytotoxicity in retinoblastoma SO-Rb50 cells. Inhibition of Akt can decrease the survival of both sensitive and vincristine-resistant SO-Rb50 cells and increase the sensitivity of both cell lines to vincristine by enhancing the cell apoptosis and increasing the cellular accumulation of the drug. Akt may be a target for reducing drug resistance that improves the treatment for retinoblastoma.
引用
收藏
页码:156 / 165
页数:10
相关论文
共 50 条
  • [11] Pristimerin overcomes adriamycin resistance in breast cancer cells through suppressing Akt signaling
    Xie, Gui'e
    Yu, Xinpei
    Liang, Huichao
    Chen, Jingsong
    Tang, Xuewei
    Wu, Shaoqing
    Liao, Can
    ONCOLOGY LETTERS, 2016, 11 (05) : 3111 - 3116
  • [12] Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer
    Xufeng Chen
    Hitesh Thakkar
    Frazier Tyan
    Suzanna Gim
    Heather Robinson
    Calvin Lee
    Sanjay K Pandey
    Chichi Nwokorie
    Nneka Onwudiwe
    Rakesh K Srivastava
    Oncogene, 2001, 20 : 6073 - 6083
  • [13] Vincristine- and cisplatin-induced apoptosis in human retinoblastoma. Potentiation by sodium butyrate
    Conway, RM
    Madigan, MC
    Billson, FA
    Penfold, PL
    EUROPEAN JOURNAL OF CANCER, 1998, 34 (11) : 1741 - 1748
  • [14] Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer
    Chen, XF
    Thakkar, H
    Tyan, F
    Gim, S
    Robinson, H
    Lee, C
    Pandey, SK
    Nwokorie, C
    Onwudiwe, N
    Srivastava, RK
    ONCOGENE, 2001, 20 (42) : 6073 - 6083
  • [15] BRCA1 expression serves a role in vincristine resistance in colon cancer cells
    Xu, Zhongjie
    Zhang, Lirong
    ONCOLOGY LETTERS, 2017, 14 (01) : 345 - 348
  • [16] Survivin expression modulates the sensitivity of A549 lung cancer cells resistance to vincristine
    Zhou, Chengwei
    Zhu, Yonggang
    Lu, Bin
    Zhao, Weijun
    Zhao, Xiaodong
    ONCOLOGY LETTERS, 2018, 16 (04) : 5466 - 5472
  • [17] Effects of matrine on the proliferation and apoptosis of vincristine-resistant retinoblastoma cells
    Zhao, Bowen
    Li, Bin
    Liu, Qian
    Gao, Fei
    Zhang, Zhibao
    Bai, Haixia
    Wang, Yichen
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2020, 20 (03) : 2838 - 2844
  • [18] Oridonin induces apoptosis and reverses drug resistance in cisplatin resistant human gastric cancer cells
    He, Zhongwei
    Xiao, Xiangling
    Li, Shan
    Guo, Yang
    Huang, Qiuyue
    Shi, Xin
    Wang, Xiaobo
    Liu, Ying
    ONCOLOGY LETTERS, 2017, 14 (02) : 2499 - 2504
  • [19] L-type calcium channel blockers reverse docetaxel and vincristine-induced multidrug resistance independent of ABCB1 expression in human lung cancer cell lines
    Chiu, Ling-Yen
    Ko, Jiunn-Liang
    Lee, Yi-Ju
    Yang, Tsung-Ying
    Tee, Yi-Torng
    Sheu, Gwo-Tarng
    TOXICOLOGY LETTERS, 2010, 192 (03) : 408 - 418
  • [20] Glioma cells escaped from cytotoxicity of temozolomide and vincristine by communicating with human astrocytes
    Chen, Weiliang
    Wang, Donghai
    Du, Xinwen
    He, Ying
    Chen, Songyu
    Shao, Qianqian
    Ma, Chao
    Huang, Bin
    Chen, Anjing
    Zhao, Peng
    Qu, Xun
    Li, Xingang
    MEDICAL ONCOLOGY, 2015, 32 (03)